ASP Isotopes Issues Letter to Shareholders
ASP Isotopes provided a comprehensive update outlining a path to over $300 million in EBITDA by 2031, driven by strong performance across its divisions. PET Labs reported organic revenue growth of over 50% in 1H 2026 and is on track to deliver $14 million in revenue for the full year, up from $6 million in 2025. The Renergen subsidiary is expected to commence helium and LNG production prior to September 30, 2026, with projected Phase 1 annualized revenue of approximately $27 million. The company also announced a reverse merger between Noble Africa and ENDRA Life Sciences (NDRA) to list Noble Africa on Nasdaq under ticker NOBA, supported by a $50 million private placement.
Key figures
- Guidance
- Long-Term EBITDA target >$300 million by 2031; PET Labs FY 2026 revenue approx. $14 million; Renergen Phase 1 annualized revenue approx. $27 million; Renergen Phase 2 potential revenue >$360 million at nameplate capacity.
- Target 2031 ebitda
- $300 million
- Pet labs 1h2026 growth
- over 50%
- Pet labs fy2026 revenue
- $14 million
- Aspi investment noble africa
- $20 million
- Noble africa private placement
- $50 million
- Renergen phase2 potential revenue
- $360 million
- Renergen phase1 annualized revenue
- $27 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.